A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
NCT07415031 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 170
Last updated 2026-05-15
Summary
This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other advanced solid tumors.
Conditions
Interventions
- DRUG
-
Adagrasib
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Pemetrexed
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Specified dose on specified days
Sponsors & Collaborators
-
Mirati Therapeutics Inc.
lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-05-06
- Primary Completion
- 2028-02-16
- Completion
- 2028-02-16
- FDA Drug
- Yes
Countries
- United States
- Australia
- Belgium
- Canada
- France
- Germany
- Greece
- Israel
- Italy
- Netherlands
- Portugal
- Romania
- Singapore
- Spain
Study Locations
More Related Trials
-
Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer
NCT05491083 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201
NCT06341647 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors
NCT06024174 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)
NCT04975256 ·Status: TERMINATED ·Phase: PHASE1
-
Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
NCT07334119 ·Status: RECRUITING ·Phase: PHASE1
-
Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors
NCT02386501 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
NCT07223047 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
The Trial Comparing Dose-dense AC-T With PC as Adjuvant Therapy for TNBC
NCT01378533 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
NCT03498716 ·Status: TERMINATED ·Phase: PHASE3
-
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
NCT06764771 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer
NCT06508216 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)
NCT05178888 ·Status: COMPLETED ·Phase: PHASE1
-
Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy
NCT04437160 ·Status: RECRUITING ·Phase: PHASE2
-
Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer
NCT02455141 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd
NCT06298084 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer
NCT02514681 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer
NCT07393321 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC
NCT06793553 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
NCT04872166 ·Status: RECRUITING ·Phase: PHASE1
-
Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors
NCT05687136 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
NCT03448042 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer
NCT03197935 ·Status: COMPLETED ·Phase: PHASE3
-
This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer
NCT03099174 ·Status: COMPLETED ·Phase: PHASE1
-
A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
NCT07003074 ·Status: RECRUITING ·Phase: PHASE3
-
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
NCT01451632 ·Status: COMPLETED ·Phase: PHASE1